Skip to content
RDL Network logo
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study — Richard S. Finn (2021) | RDL Network